» Articles » PMID: 2709672

The Clinical Utility of Renal Concentrating Capacity in Polycystic Kidney Disease

Overview
Journal Kidney Int
Publisher Elsevier
Specialty Nephrology
Date 1989 Feb 1
PMID 2709672
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

We studied 177 adult nonazotemic subjects with autosomal dominant polycystic kidney disease (ADPKD) and 123 unaffected family members (NADPKD). In order to assess the factors influencing renal concentrating capacity maximal urinary osmolality (UOsm) after overnight water deprivation and vasopressin was measured. UOsm was reduced in ADPKD (680 +/- 14) compared to NADPKD subjects (812 +/- 13 mOsm/kg). A greater severity of the architectural abnormality as assessed by cyst number and size and remaining volume of normal parenchyma was associated with a greater impairment of renal concentrating capacity. The concentrating defect was present in the youngest ADPKD subjects and the rate of decline of concentrating capacity with age in ADPKD paralleled that in NADPKD subjects. Based on the initial 135 subjects studied, we developed an algorithm for diagnostic screening for ADPKD utilizing blood pressure, serum creatinine and UOsm designed to maximize sensitivity. When applied to a subsequent population of 165 adults, 121 with ADPKD and 44 unaffected relatives, this algorithm would have spared 20% of unaffected subjects from the cost of ultrasound while failing to detect less than 2% of affected subjects. This simple protocol thus offers a rapid and inexpensive way to screen for ADPKD.

Citing Articles

Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database.

Cao P, Wang Q, Wang Y, Qiao Q, Yan L Front Pharmacol. 2025; 15():1509310.

PMID: 39850569 PMC: 11754202. DOI: 10.3389/fphar.2024.1509310.


Biomarkers of Kidney Disease Progression in ADPKD.

Ghanem A, Borghol A, Munairdjy Debeh F, Paul S, Alkhatib B, Harris P Kidney Int Rep. 2024; 9(10):2860-2882.

PMID: 39435347 PMC: 11492289. DOI: 10.1016/j.ekir.2024.07.012.


Predicting autosomal dominant polycystic kidney disease progression: review of promising Serum and urine biomarkers.

Soric Hosman I, Cvitkovic Roic A, Fistrek Prlic M, Vukovic Brinar I, Lamot L Front Pediatr. 2023; 11:1274435.

PMID: 38027263 PMC: 10667601. DOI: 10.3389/fped.2023.1274435.


Tubular changes in autosomal dominant polycystic kidney disease patients: observational study.

Lai S, Perrotta A, Rotondi S, Zippo F, Mene P, Tartaglione L J Nephrol. 2023; 37(2):531-533.

PMID: 37955820 DOI: 10.1007/s40620-023-01794-7.


Thirst intensity survey in ADPKD patients.

Gocay Bek S, Yildiz N, Islam M, Ergul M, Sarioglu I, Guven Taymez D Clin Exp Nephrol. 2023; 27(10):819-827.

PMID: 37351680 DOI: 10.1007/s10157-023-02373-7.